Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

PMID:
28497758
2.

Demographical, Viro-Immunological, Clinical and Therapeutical Characteristics of HIV-Infected Patients in an "Epidemiologically Unexplored" Region of Italy (Calabria Region): the CalabrHIV Cohort.

Postorino MC, Luciani F, Mangano C, Carpentieri MS, Scerbo P, Priamo A, Berardelli G, Marino R, Vallone A, Serrao N, Pisani V, Costa C, Terremoto A, Foti G, Cosco L, Calderazzo M, Corigliano D, Scordo P, Strazzulla A, Torti C; CalabrHIV Study Group.

Mediterr J Hematol Infect Dis. 2015 Oct 8;7(1):e2015054. doi: 10.4084/MJHID.2015.054. eCollection 2015.

3.

Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy.

Camoni L, Raimondo M, Dorrucci M, Regine V, Salfa MC, Suligoi B; CARPHA Study Group.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):282-7. doi: 10.1089/AID.2014.0154. Epub 2015 Jan 6.

4.

Challenging clinical cases in HCV infection.

Strazzulla A, Matera G, Mammone SV, Vaccaro V, Pisani V, Costa C, Manti F, Doldo P, Cosco L, Quintieri F, Cesario F, Liberto MC, Giancotti A, Torti C, Focà A.

BMC Infect Dis. 2014;14 Suppl 5:S7. doi: 10.1186/1471-2334-14-S5-S7. Epub 2014 Sep 5.

5.

Update on epidemiology of HCV in Italy: focus on the Calabria Region.

Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A, Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, Focà A.

BMC Infect Dis. 2014;14 Suppl 5:S2. doi: 10.1186/1471-2334-14-S5-S2. Epub 2014 Sep 5. Review.

6.

Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C.

Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A; Acute Hepatitis Italian Study Group.

Clin Infect Dis. 2013 Sep;57(6):803-11. doi: 10.1093/cid/cit402. Epub 2013 Jun 19.

7.

Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology).

Torti C, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano D, Cosco L, Costa C, Curia RL, De Rosa M, Foti G, Giraldi C, Leone R, Liberto MC, Lucchino D, Marascio N, Masciari R, Matera G, Pisani V, Serrao N, Surace L, Zicca E, Castelli F, Ciccozzi M, Puoti M, Focà A; SINERGIE Study Group.

BMC Infect Dis. 2012;12 Suppl 2:S9. doi: 10.1186/1471-2334-12-S2-S9. Epub 2012 Nov 12. Review.

8.

Current practice of chronic hepatitis B treatment in Southern Italy.

Stroffolini T, Spadaro A, Di Marco V, Scifo G, Russello M, Montalto G, Bertino G, Surace L, Caroleo B, Foti G, Portelli V, Madonia S, Sapienza M, Cosco L, Frugiuele P, Galdieri A, Brandolino N, Siciliano R, Bruno S, Almasio PL; Gr.E.Ca.S. Hospitals' Collaborating Group.

Eur J Intern Med. 2012 Jul;23(5):e124-7. doi: 10.1016/j.ejim.2012.03.018. Epub 2012 Apr 25.

PMID:
22726382
9.

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts.

BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23.

10.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

11.

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA.

AIDS. 2008 Nov 30;22(18):2481-92. doi: 10.1097/QAD.0b013e328318f130.

12.

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.

Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD.

Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862.

13.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD.

Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.

14.

Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis.

Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, Moioli C, Rizzardini G, Chiodera A, Ballardini G, Tincati C, d'Arminio Monforte A; I.Co.N.A. Study Group.

Infection. 2008 Feb;36(1):46-53. doi: 10.1007/s15010-007-6300-z. Epub 2008 Jan 29.

PMID:
18231722
15.

Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.

Solmone M, Girardi E, Lalle E, Abbate I, D'Arminio Monforte A, Cozzi-Lepri A, Alessandrini A, Piscopo R, Ebo F, Cosco L, Antonucci G, Ippolito G, Capobianchi MR; Hepal.Co.N.A. Study Group; I.Co.N.A Study Group.

Antivir Ther. 2006;11(1):87-94.

PMID:
16518964
16.

HIV-1: a case of RT67 deletion in a multi-treated non responder patient.

Masciari R, Cosco L, Diaco MC, Della DN, Ferraro T, Raimondi T, Ruperti B, Santandrea E.

New Microbiol. 2002 Jan;25(1):83-8.

PMID:
11837395
17.

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus.

Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, Ferraro T, Concia E.

Lancet. 1996 Jan 13;347(8994):92-3.

PMID:
8538348
18.

Hazards of interferon therapy for HBV-seronegative chronic hepatitis.

Vento S, Di Perri G, Garofano T, Cosco L, Concia E, Ferraro T, Bassetti D.

Lancet. 1989 Oct 14;2(8668):926. No abstract available.

PMID:
2571851

Supplemental Content

Loading ...
Support Center